Business
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or t...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update\nTORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2025 and provided a corporate update. The past year marked a significant milestone in Spectral’s clinical and regulatory progression, highlighted by the completion of enrollment of the Tigris trial, the release of positive topline Tigris results and the advancement of PMX into the final stages of regulatory readiness. During the fourth quarter and subsequent to year end, the Company achieved additional key milestones supporting the clinical and scientific strength of PMX, including the publication of the Tigris manuscript in The Lancet Respiratory Medicine and its selection for presentation at the Society of Critical Care Medicine (“SCCM”) Annual Congress. Together, these milestones further strengthen the overall body of evidence supporting PMX and position the Company as it advances toward its planned FDA Premarket Approval (“PMA”) submission. “Our focus in the second quarter is on completing a high-quality PMA submission and continuing to build the clinical and commercial foundation necessary to support the adoption of PMX,” said Chris Seto, Chief Executive Officer of Spectral Medical. “We believe the growing body of evidence, including publication in The Lancet Respiratory Medicine and presentation at SCCM, further supports the strength and consistency of the Tigris results and advances our efforts to bring this therapy to patients in the United States.” Dr. John Kellum, Chief Medical Officer of Spectral Medical, added, “Publication of the Tigris results in a leading peer-reviewed journal, alongside the presentation of these results at a major international congress, represents an important step in translating these findings to clinical practice. The consistency of benefit observed across endpoints, including longer-term outcomes, suggests that the treatment effect becomes more apparent as patients recover beyond the acute phase of septic...